-+ 0.00%
-+ 0.00%
-+ 0.00%

Natera Receives FDA's Breakthrough Device Designation For Its Multi-Cancer Early Detection Assay

Benzinga·10/09/2026 12:02:22
Listen to the news

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its multi-cancer early detection (MCED) assay has been granted Breakthrough Device designation (BDD) by the U.S. Food and Drug Administration (FDA). The BDD is designed for novel technologies that enable more effective diagnosis or treatment of life-threatening or irreversibly debilitating diseases or conditions.